Americas Source-linked briefing

LILLY CANADA WELCOMES POSITIVE CDA-AMC RECOMMENDATION TO REIMBURSE KISUNLA® (DONANEMAB) FOR EARLY ALZHEIMER'S DISEASE

/CNW/ -- Eli Lilly Canada Inc. is pleased to announce that Canada's Drug Agency (CDA-AMC) has issued a positive recommendation to reimburse Kisunla®...

Cnw Group

Original contributor via Newswire

| November 6, 2026 | 1 min read | Updated Nov 7, 2:00 AM

LILLY CANADA WELCOMES POSITIVE CDA-AMC RECOMMENDATION TO REIMBURSE KISUNLA® (DONANEMAB) FOR EARLY ALZHEIMER'S DISEASE — Image supplied with the source report: Newswire.

/CNW/ -- Eli Lilly Canada Inc. is pleased to announce that Canada's Drug Agency (CDA-AMC) has issued a positive recommendation to reimburse Kisunla®...

Source disclosure

This is a source-linked briefing. Read the original report from Newswire .